ContraFect (CFRX) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ContraFect Corporation Announces Third Quarter 2015 Financial and Operating Results
November 12, 2015 6:00 PM ESTYONKERS, NY -- (Marketwired) -- 11/12/15 -- ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW)
FDA Fast Track Designation Granted to CF-301, currently in Phase 1 clinical trials for Staph bacteremia, including MRSA Key Management Additions: Dr. Cara Cassino, Chief Medical Officer; Joshua Muntner, Head of Business Development; and Paul Boni, Head of Investor Development and Strategy $9.6 Million Raised Through the Exercise of Class B... More